Clinical Trials · NCT00220194

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

Name: A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Gonadorelin

Phase: Phase 4
Recruitment status: Completed
Sponsor: San Bernardino Urological Associates Medical Group Inc
Enrollment: 100
Start date: Apr 2003
Locations: 1 site, United States
Primary endpoint: Study in Cancer of Prostate

View Gonadorelin compound reference